Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show a fall in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $4.00, about 56.3% above its last closing price of $2.56
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.53 | -0.53 | -0.37 | Beat | 29.9 |
Jun. 30 2025 | -0.56 | -0.58 | -0.37 | Beat | 36.4 |
Mar. 31 2025 | -0.65 | -0.64 | -0.56 | Beat | 12.2 |
Dec. 31 2024 | -0.62 | -0.71 | -0.62 | Beat | 12.2 |
Sep. 30 2024 | -0.88 | -0.91 | -0.56 | Beat | 38.5 |
Jun. 30 2024 | -0.87 | -0.84 | -1.24 | Missed | -47.5 |
Mar. 31 2024 | -0.76 | -0.77 | 0.14 | Beat | 118.3 |
Dec. 31 2023 | -0.94 | -0.92 | -0.93 | Missed | -1.5 |
This summary was machine generated March 20 at 11:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments